Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00384176 · ClinicalTrials.gov registry record · Phase 2
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,814
- Enrollment target
NCT00384176: Completed Phase 2 study, sponsored by AstraZeneca.
NCT00384176 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 1,814 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1264% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00384176, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,814 participants
- Enrollment target
Study Summary
The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
Primary Outcome
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression.
Interventions
- DRUG Bevacizumab
- DRUG Cediranib
- DRUG 5-fluorouracil ( in FOLFOX)
- DRUG Leucovorin (in FOLFOX)
- DRUG Oxaliplatin (in FOLFOX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,814 participants |
| Start Date | 2006-08-30 |
| Est. Completion | 2015-08-19 |
| Phase | Phase 2 |
What the finished NCT00384176 record still lists
NCT00384176 is an interventional study that assigns participants to a tested intervention. Its 1,814 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1264% higher).
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00384176 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00384176 about?
NCT00384176 is a clinical study titled "First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX". The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.
What is the current status of trial NCT00384176?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,814 participants. The study started on 2006-08-30. Estimated completion is 2015-08-19.
What interventions are being tested in trial NCT00384176?
The interventions under investigation include: Bevacizumab (DRUG), Cediranib (DRUG), 5-fluorouracil ( in FOLFOX) (DRUG), Leucovorin (in FOLFOX) (DRUG), Oxaliplatin (in FOLFOX) (DRUG).
Who is sponsoring clinical trial NCT00384176?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00384176's enrollment target sits among peer trials
1,814 10th of 2000 higher than 1,991 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI